Prevalence of metabolic syndrome in schizophrenic patients;Prevalência de síndrome metabólica em pacientes com esquizofrenia

Scientia Medica

Volumn 21, Issue 1, 2011, Pages 1-12

  Vargas, Tatiana de Souza ^a   Santos, Zilda Elizabeth de Albuquerque ^b  

^a CENTRO UNIVERSITÁRIO METODISTA IPA   (Brazil)

^b Instituto Porto Alegre da Igreja Metodista   (Brazil)

Author keywords

Antipsychotic agents; Cross sectional studies; Inpatients; Male; Metabolic syndrome X epidemiology; Schizophrenia

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; BODY WEIGHT; BRAZIL; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PREVALENCE; SCHIZOPHRENIA; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 79952093287     PISSN: 18065562     EISSN: 19806108     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on detection, evaluation, and treatment of high blood cholesterol In adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
2. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome.[16 p.].[acesso 2010 mar 9]. Disponível em: http://www.idf.org/webdata/docs/MetS_def_update2006.pdf
3. Sociedade Brasileira de Cardiologia. I Diretriz brasileira de diagnóstico e tratamento da síndrome metabólica. Arq Bras Cardiol. 2005;84(supl 1):1-27.
4. a.ed. Porto Alegre: Artes Médicas; 1995.
5. th ed. Washington: American Psychiatric Association; 2000.
6. a.ed. Porto Alegre: Artmed; 1997. p.439-66.
7. Cohn T, Prud'Homme D, Streiner D, et al. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalenc of metabolic syndrome. Can J Psychiatry. 2004;49:753-60.
8. Leitão CL, Guimarães LR, Lobato MI, et al. Ganho de peso e alterações metabólicas em esquizofrenia. Rev Psiq Clin. 2007;34:184-8.
9. Elkis H, Gama C, Suplicy H, et al. Consenso brasileiro sobre antipsicóticos de segunda geração e distúrbios metabólicos. Rev Bras Psiquiatr. 2008;30:77-85.
10. Toalson P, Ahmed S, Hardy T, et al. The metabolic syndrome in patients with severe mental illnesses. Prim Care Companion J Clin Psychiatry. 2004;6:152-8.
11. Falkai P, Wobrock T, Liebermen J, et al. World Federation of Societies of Biological Psychiatry (WFSBP). WFSBP Task Force on Treatment Guidelines for Schizophrenia. World J Biol Psychiatry. 2005;6:132-91.
12. World Health Organization. Global Database on Body Mass Index, BMI Classification, 2004: an interactive surveillance tool for monitoring nutrition transition. [acesso 2010 maio 30]. Disponível em: http://apps.who.int/bmi/index.jsp?introPage=intro_3.html
13. Lipschitz DA. Screening for nutritional status in the elderly. Prim Care. 1994; 21:55-67.
14. Hert MA, Van Winkel R, Van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006; 83:87-93.
15. Kato MM, Currier MB, Gomez CM, et al. Prevalence of metabolic syndrome in hispanic and nonhispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry. 2004;6:74-7.
16. Meyer J, Loh C, Leckband SG, et al. Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract. 2006;12:5-10.
17. Leitão CL, Abreu MG, Guimarães LR, et al. Sobrepeso e obesidade em pacientes esquizofrênicos em uso de clozapina comparado com o uso de outros psicóticos. Rev Psiquiatr Rio Gd Sul. 2006;28:120-8.
18. Attux C, Quintana M, Chaves A. Ganho de peso, dislipidemia e parâmetros alterados para síndrome metabólica em pacientes de primeiro episódio psicótico após seguimento de seis meses. Rev Bras Psiquiatr. 2007;29:346-9.
19. Allisson DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-96.
20. Straker D, Correl CU, Ginsberg EK, et al. Cost effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry. 2005;162:1217-21.
21. Leitão CL, Guimarães LR, Abreu MG, et al. Increased dyslipidemia in chizophrenic outpatients using new generation antipsychotics. Rev Bras Psiquiatr. 2006;28:301-4.
22. Arango C, Bobes J, Aranda P, et al. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. Schizophrenia Res. 2008;104:1-12.